1. Identification of cofilin-1 as a novel mediator for the metastatic potentials and chemoresistance of the prostate cancer cells
- Author
-
Hongjiao Liu, Xiangpeng Tan, Xiaoping Wu, Yishan Huang, Jialong Cai, Xiangfeng Zeng, Qiuxiao Guo, Xiaomian Lin, Cairong Zhu, and Liankuai Chen
- Subjects
0301 basic medicine ,Cofilin 1 ,Male ,Proteomics ,Programmed cell death ,ATP Binding Cassette Transporter, Subfamily B ,macromolecular substances ,Biology ,Metastasis ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Multidrug Resistance Protein 1 ,Cell Movement ,medicine ,Humans ,Pharmacology ,Antibiotics, Antineoplastic ,Prostatic Neoplasms ,medicine.disease ,030104 developmental biology ,Lytic cycle ,Apoptosis ,Cell culture ,Doxorubicin ,Drug Resistance, Neoplasm ,PC-3 Cells ,Cancer research ,030217 neurology & neurosurgery - Abstract
Prostate cancer (PCa) is the most common malignancy among men. Tumor metastasis and chemoresistance contribute to the major cause of the mortality. In this study, we compared the protein profiles of two prostate cancer cell lines with different metastatic potentials, and identified cofilin-1 (CFL1) was one of the most differentially expressed proteins between two cell lines. Further results suggested that cofilin-1 promoted the remodeling of F-actin cytoskeleton, and enhanced the proliferation, migration and invasion of the prostate cancer cells via activation of P38 MAPK signaling pathway. In addition, cofilin-1 elevated the expression and drug efflux activity of multidrug resistance protein 1 (MDR1) by P38 MAPK signaling pathway, resulting in decrease of the adriamycin-induced apoptosis as well as the lytic cell death, and the subsequent resistance against adriamycin. Collectively, cofilin-1 might serve as a novel target candidate for both inhibiting the metastasis and reversing the chemoresistance of PCa.
- Published
- 2019